Table 1 The clinical characteristics of TCGA, METABRIC, GSE58812, GSE20685 and ICGC-KR cohorts
| Â | TCGA | METABRIC | GSE58812 | GSE20685 | ICGC-KR |
|---|---|---|---|---|---|
Sample | |||||
 Tumor | 1109 | 1764 | 107 | 327 | 50 |
 Normal | 113 | 148 | 0 | 0 | 50 |
Survival Status | |||||
 Dead | 144 | 1027 | 29 | 83 | 10 |
 Alive | 933 | 737 | 78 | 244 | 40 |
Age (Median) | 58.38 | 61.41 | 59.96 | 47.89 | 31.81 |
 <60 | 575 | 761 | 64 | 278 | 50 |
  ≥ 60 | 502 | 1003 | 43 | 49 | 0 |
Grade | |||||
 G1 | / | 154 | / | / | / |
 G2 | / | 664 | / | / | / |
 G3 | / | 882 | / | / | / |
 Unknown | / | 64 | / | / | / |
T | |||||
 T1/Tis | 275 | / | / | 101 | 19/3 |
 T2 | 624 | / | / | 188 | 24 |
 T3 | 136 | / | / | 26 | 3 |
 T4 | 39 | / | / | 12 | 1 |
 Unknown | 3 | / | / | / | / |
N | |||||
 N0 | 507 | / | / | 137 | / |
 N1–3 | 550 | / | / | 190 | / |
 Unknown | 20 | / | / | / | / |
M | |||||
 M0 | 897 | / | 76 | 244 | / |
 M1 | 21 | / | 31 | 83 | / |
 Unknown | 159 | / | / | / | / |
Clinical Stage | |||||
 Stage I | 179 | 436 | / | / | 13 |
 Stage II | 609 | 745 | / | / | 28 |
 Stage III | 246 | 111 | / | / | 6 |
 Stage IV | 19 | 7 | / | / | 0 |
 Unknown | 24 | 465 | / | / | / |
Subtype | |||||
 Luminal A | 497 | 679 | / | / | / |
 Luminal B | 197 | 461 | / | / | / |
 Basal | 171 | 199 | / | / | / |
 Her2 | 77 | 220 | / | / | / |
 Unknown | 135 | claudin-low = 199 Unknown = 6 | / | / | / |
OS (Year) | Median = 3.273 | Median = 10.428 | Median = 6.035 | Median = 7.89 | Median = 7.558 |
PFS (Month) | Median = 37.859 | / | / | / | / |
DFS (Month) | Median = 37.851 | / | / | / | / |